biotech / news / / The Manila Times
Formosa Pharmaceuticals, Inc.
TSY-310 is a bispecific ADC targeting both EGFR and ROR1 in solid tumors.
KEY POINTS
- Preclinical results show TSY-310 induces a strong bystander effect, killing antigen-negative nearby tumor cells.
- The ADC exhibits enhanced lysosomal trafficking in tumor cells, ensuring efficient cytotoxic payload release.
- TSY-310 will be presented at ASCO 2026, highlighting its selectivity and efficacy in heterogeneous breast tumors.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →